[go: up one dir, main page]

BRPI0817223A2 - Inibidores da interação entre mdm2 e p53 - Google Patents

Inibidores da interação entre mdm2 e p53

Info

Publication number
BRPI0817223A2
BRPI0817223A2 BRPI0817223-4A2A BRPI0817223A BRPI0817223A2 BR PI0817223 A2 BRPI0817223 A2 BR PI0817223A2 BR PI0817223 A BRPI0817223 A BR PI0817223A BR PI0817223 A2 BRPI0817223 A2 BR PI0817223A2
Authority
BR
Brazil
Prior art keywords
mdm2
interaction inhibitors
inhibitors
interaction
Prior art date
Application number
BRPI0817223-4A2A
Other languages
English (en)
Inventor
Virginie Sophie Poncelet
Sophie Coupa
Pierre-Henri Storck
Bruno Schoentjes
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38910911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0817223(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0817223A2 publication Critical patent/BRPI0817223A2/pt
Publication of BRPI0817223B1 publication Critical patent/BRPI0817223B1/pt
Publication of BRPI0817223B8 publication Critical patent/BRPI0817223B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0817223A 2007-09-21 2008-09-18 inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação BRPI0817223B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07116889 2007-09-21
PCT/EP2008/062433 WO2009037308A1 (en) 2007-09-21 2008-09-18 Inhibitors of the interaction between mdm2 and p53

Publications (3)

Publication Number Publication Date
BRPI0817223A2 true BRPI0817223A2 (pt) 2015-03-10
BRPI0817223B1 BRPI0817223B1 (pt) 2020-04-07
BRPI0817223B8 BRPI0817223B8 (pt) 2021-05-25

Family

ID=38910911

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817223A BRPI0817223B8 (pt) 2007-09-21 2008-09-18 inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação

Country Status (23)

Country Link
US (4) US9573933B2 (pt)
EP (1) EP2203440B1 (pt)
JP (1) JP5438007B2 (pt)
CN (2) CN101868453A (pt)
AR (1) AR068627A1 (pt)
AT (1) ATE502934T1 (pt)
AU (1) AU2008300527B2 (pt)
BR (1) BRPI0817223B8 (pt)
CA (1) CA2699849C (pt)
CL (1) CL2008002798A1 (pt)
DE (1) DE602008005784D1 (pt)
DK (1) DK2203440T3 (pt)
ES (1) ES2363838T3 (pt)
HR (1) HRP20110394T1 (pt)
JO (1) JO2704B1 (pt)
MX (1) MX2010003060A (pt)
PA (1) PA8796901A1 (pt)
PE (1) PE20090817A1 (pt)
RU (1) RU2477724C2 (pt)
SI (1) SI2203440T1 (pt)
TW (1) TWI434841B (pt)
UY (1) UY31349A1 (pt)
WO (1) WO2009037308A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
MY152018A (en) 2009-02-04 2014-08-15 Janssen Pharmaceutica Nv Indole derivatives as anticancer agents
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
CN102321034B (zh) * 2011-06-07 2014-08-13 中国人民解放军第二军医大学 硫代苯二氮卓类化合物及其作为药物的用途
CA2853729A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
ES2410704B1 (es) * 2011-11-28 2014-04-29 Universitat De Barcelona Indoleninas fluoradas útiles para el tratamiento del cáncer.
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CN115137529B (zh) 2016-12-21 2025-12-02 特里弗洛心血管公司 心脏瓣膜支撑装置及用于制造和使用该装置的方法
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1734401A (en) * 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
ES2566056T3 (es) * 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
AU2002357728A1 (en) * 2001-11-09 2003-05-19 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
US7540139B2 (en) * 2004-08-16 2009-06-02 Rowse Hydraulic Rakes Co., Inc. Foldable hay rake
JP5156378B2 (ja) * 2004-09-22 2013-03-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ MDM2とp53の間の相互作用の阻害剤
WO2006089286A2 (en) * 2005-02-18 2006-08-24 Acadia Pharmaceuticals Inc. Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor compounds useful for the treatment and prevention of pain and screening methods therefor
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US8232298B2 (en) 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
PA8792401A1 (es) * 2007-08-06 2009-03-31 Janssen Pharmaceutica Nv Fenilendiaminas
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53

Also Published As

Publication number Publication date
PE20090817A1 (es) 2009-07-02
DK2203440T3 (da) 2011-06-20
US11583524B2 (en) 2023-02-21
AU2008300527A1 (en) 2009-03-26
EP2203440A1 (en) 2010-07-07
HRP20110394T1 (hr) 2011-06-30
AR068627A1 (es) 2009-11-25
TWI434841B (zh) 2014-04-21
MX2010003060A (es) 2010-04-07
CN104761541A (zh) 2015-07-08
ATE502934T1 (de) 2011-04-15
RU2010115765A (ru) 2011-10-27
US20170112818A1 (en) 2017-04-27
CL2008002798A1 (es) 2009-06-05
JP5438007B2 (ja) 2014-03-12
ES2363838T3 (es) 2011-08-17
AU2008300527B2 (en) 2013-08-29
BRPI0817223B1 (pt) 2020-04-07
CN101868453A (zh) 2010-10-20
TW200930709A (en) 2009-07-16
CA2699849A1 (en) 2009-03-26
SI2203440T1 (sl) 2011-07-29
EP2203440B1 (en) 2011-03-23
UY31349A1 (es) 2009-03-31
BRPI0817223B8 (pt) 2021-05-25
RU2477724C2 (ru) 2013-03-20
JP2010539220A (ja) 2010-12-16
US20200121667A1 (en) 2020-04-23
US20100240637A1 (en) 2010-09-23
PA8796901A1 (es) 2009-05-15
CA2699849C (en) 2015-10-27
DE602008005784D1 (de) 2011-05-05
US9573933B2 (en) 2017-02-21
JO2704B1 (en) 2013-03-03
WO2009037308A1 (en) 2009-03-26
US20180263966A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
BRPI0817223A2 (pt) Inibidores da interação entre mdm2 e p53
NO2020028I1 (no) saksagliptin og dapagliflozin
DK3345625T3 (da) Farmaceutisk sammensætning og indgivelser deraf
BRPI0820150A2 (pt) Unidade selada e espaçador
DK2107905T3 (da) Fast sammensætning omfattende alogliptin og pioglitazon
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK2254873T3 (da) Benzodiazepinforbindelse og farmaceutisk sammensætning.
EP1995290A4 (en) PRESSURE-SENSITIVE ADHESIVE COMPOSITION AND PRESSURE-SENSITIVE ADHESIVE SHEET USING THE SAME
BRPI0812970A2 (pt) conjugados contendo espaçadores hidrofílicos
DE602007012419D1 (de) Hochfestes haftpolymergel und klebeband
DK2207773T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning deraf.
DK2192932T3 (da) Materialer til oftalmologisk og otorhinolaryngologisk anordning
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK2292592T3 (da) Sulfonamidforbindelse og anvendelse deraf
BRPI0815203A2 (pt) gel contendo pirfenidona
ATE543500T1 (de) Kombinationen mit 5ht6-modulatoren und cholinesterase-hemmern
DK2152699T3 (da) Quinolon-forbindelse og farmaceutisk sammensætning
DK2334596T3 (da) Ferriphosphatbaseret sammensætning og anvendelse heraf
BRPI0809684A2 (pt) Embalagem, e embalagem
FI20055630A0 (fi) Kasvonaamio
ATE527249T1 (de) Indole
EP1915162A4 (en) Modulators
BRPI0912074A2 (pt) composto e composição farmacêutica
EP2135915A4 (en) FLUORESCENT FILM

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2792 DE 09-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.